...
首页> 外文期刊>Journal of Clinical Oncology >Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: A National Comprehensive Cancer Network analysis
【24h】

Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: A National Comprehensive Cancer Network analysis

机译:新辅助疗法治疗的II / III期直肠癌患者术后辅助化疗的使用:国家综合癌症网络分析

获取原文
获取原文并翻译 | 示例

摘要

Purpose: Practice guidelines recommend that patients who receive neoadjuvant chemotherapy and radiation for locally advanced rectal cancer complete postoperative adjuvant systemic chemotherapy, irrespective of tumor downstaging. Patients and Methods: The National Comprehensive Cancer Network (NCCN) Colorectal Cancer Database tracks longitudinal care for patients treated at eight specialty cancer centers across the United States and was used to evaluate how frequently patients with rectal cancer who were treated with neoadjuvant chemotherapy also received postoperative systemic chemotherapy. Patient and tumor characteristics were examined in a multivariable logistic regression model. Results: Between September 2005 and December 2010, 2,073 patients with stage II/III rectal cancer were enrolled in the database. Of these, 1,193 patients receiving neoadjuvant chemoradiotherapy were in the analysis, including 203 patients not receiving any adjuvant chemotherapy. For those seen by a medical oncologist, the most frequent reason chemotherapy was not recommended was comorbid illness (25 of 50, 50%); the most frequent reason chemotherapy was not received even though it was recommended or discussed was patient refusal (54 of 74, 73%). After controlling for NCCN Cancer Center and clinical TNM stage in a multivariable logistic model, factors significantly associated with not receiving adjuvant chemotherapy were age, Eastern Cooperative Oncology Group performance status ≥ 1, on Medicaid or indigent compared with private insurance, complete pathologic response, presence of re-operation/wound infection, and no closure of ileostomy/colostomy. Conclusion: Even at specialty cancer centers, a sizeable minority of patients with rectal cancer treated with curative-intent neoadjuvant chemoradiotherapy do not complete postoperative chemotherapy. Strategies to facilitate the ability to complete this third and final component of curative intent treatment are necessary.
机译:目的:实践指南建议,对于局部晚期直肠癌,接受新辅助化疗和放疗的患者应完成术后辅助全身化疗,而不论肿瘤的分期如何。患者与方法:美国国家综合癌症网络(NCCN)结肠直肠癌数据库跟踪了在美国八个专科癌症中心接受治疗的患者的纵向护理,并用于评估接受新辅助化疗的直肠癌患者接受手术的频率全身化疗。在多变量逻辑回归模型中检查了患者和肿瘤的特征。结果:在2005年9月至2010年12月之间,数据库中纳入了2073例II / III期直肠癌患者。其中,分析中有1,193例接受新辅助放化疗的患者,包括203例未接受任何辅助化疗的患者。对于那些由肿瘤内科医生所见的患者,不推荐化疗的最常见原因是合并症(50%中的25%,50%);即使被推荐或讨论,仍未接受化疗的最常见原因是患者拒绝治疗(74个中的54个,73%)。在多变量Logistic模型中控制NCCN癌症中心和临床TNM分期后,与未接受辅助化疗显着相关的因素是年龄,东部合作肿瘤小组的工作状态≥1,医疗补助或贫困(与私人保险相比),完全病理反应,存在再次手术/伤口感染,并且没有关闭回肠造口术/结肠造口术。结论:即使在专科癌症中心,也有相当一部分少数接受根治性新辅助放化疗的直肠癌患者无法完成术后化疗。必须采取策略以促进完成治疗性意图治疗的第三个和最后一个组成部分的能力。

著录项

  • 来源
    《Journal of Clinical Oncology 》 |2013年第1期| 共9页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号